Site icon Market Globalist

What Caused The Anchiano Therapeutics (ANCN) To Continue Rally After-Hours?

IMH

IMH

The clinical-stage biotech company Anchiano Therapeutics Ltd. (Nasdaq: ANCN) saw its stock rising 40.12% in after-hours trades on Friday. The price of the company’s shares rose to $4.68 in extended trading, continuing the rally started in the regular session rising 18.44% to $3.34 at the ring of the bell. The rallies came in the absence of any directly linked news that could drive the stock to move but it could be attributed to the approaching financial results. Although the company has not provided the date yet to officially announce its results those are likely to be coming this week. The company is also to be going through a merger, as per a deal inked in December.

Get the hottest stocks to trade every day before the market opens 100% ‎free. Click here now. 

What driving the stock:


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Anchiano, headquartered in Cambridge, MA, is a biopharmaceutical company developed to discover, develop, and commercialize new approaches to treat cancer. Anchiano is working on small molecules that inhibit Pan-Mutant-RAS in addition to stimulating the b-catenin pathway and inhibit PDE10 activity.

Read More

Anchiano in December announced the signing of a definitive merger agreement with Chemomab Ltd. The agreement’s highlights are as follows:

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Exit mobile version